· CEO Dr. Erik D Wiklund will provide a general company update and present the
most recent circVec experimental data and R&D strategy
  · CFO Dr. Lubor Gaal will present the 2024 financial results (unaudited) and
provide an update on CircioŽs corporate development activities

Oslo, Norway 19 March 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, invites to a live webcast at 10:00am CET on Wednesday 26 March
2025. In the webcast, Circio management will provide a corporate update and
present the latest developments for the circVec platform technology.

The webcast will include an overview of ongoing testing with the novel circVec
3.0 generation, AAV and non-viral gene therapy vector development, and tissue
-specific circVec expression data in vivo, as well as an outlook on experimental
plans and milestones.

The corporate section will cover CircioŽs 2024 financial results (unaudited) and
provide an update on financing and business development activities for 2025.

Presenters:
CEO Dr. Erik Digman Wiklund
CFO Dr. Lubor Gaal

Time: 10:00 CET on 26 March 2025

click here to access the Teams webcast (https://teams.microsoft.com/l/meetup
-join/19%3ameeting_ZmVlODI4ZTktZDFmMC00MjliLWFmNDItMDA5NTJkZjdlMGQ1%40thread.v2/
0
?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966
-5b0cce82b3fe%22%2c%22Oid%22%3a%223f5f84b0-5521-4c04-bd8a-e185546abe04%22%7d)
Meeting ID: 392 868 593 190
Passcode: Mn7uS2qQ

Participate by phone:
+47 21402155
Phone conference ID: 394 288 903#

Questions can be submitted in advance by email to Erik D Wiklund:
[email protected] or directly in the live webcast

A recording of the webcast will be made available on the Circio
webpage (http://www.circio.com/)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: [email protected]

Lubor Gaal, CFO
Phone: +34 683 343 811
Email: [email protected]

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.